News - Eli Lilly, Cardio-vascular

Filter

Current filters:

Eli LillyCardio-vascular

Popular Filters

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP

27-06-2014

At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbasriaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

UK’s NICE draft guidance recommends Lilly’s Efient

UK’s NICE draft guidance recommends Lilly’s Efient

20-06-2014

UK health care watchdog the National Institute for Health and Care Excellence (NICE) has today published…

Cardio-vascularEfientEli LillyPharmaceuticalPricingRegulationUK

Atherothrombotic diseases market to grow to $47 billion in 2022

Atherothrombotic diseases market to grow to $47 billion in 2022

23-12-2013

The launch of numerous add-on therapies in the atherothrombotic diseases market (incorporating pharmacotherapies…

AstraZenecaBayerBrilintaCardio-vascularEli LillyevacetrapibGlobalMarkets & MarketingPharmaceuticalXarelto

Pre-treatment with prasugrel - more risk, no benefit: ACCOAST

02-09-2013

In patients with non-ST-elevation acute coronary syndrome (NSTE- ACS), pre-treatment with the P2Y12 antagonist…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo's anti-clotting drug shows promise in Ph III CAD study

14-07-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) presented positive results of the PRASFIT-Elective Phase…

Cardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelResearch

Daiichi Sankyo files for Japanese approval of Prasugrel

18-06-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) says that it has submitted a New Drug Application to the…

Asia-PacificCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalprasugrelRegulation

EMA starts review of Merck & Co's cholesterol drug Tredaptive

24-12-2012

The European Medicines Agency said on December 21 that it has started a review of the safety and efficacy…

anacetrapibCardio-vascularEli LillyEuropeevacetrapibMerck & CoPharmaceuticalRegulationTredaptive

STEMI guidelines now recommend AstraZeneca's ticagrelor as first-line treatment option

30-08-2012

Anglo-Swedish drug major AstraZeneca (LSE: AZN) said yesterday that ticagrelor, its oral antiplatelet…

AstraZenecaBrilintaBriliqueCardio-vascularEffientEli LillyPharmaceuticalRegulation

Anti-clotting drugs prasugrel and clopidogrel yield similar results

27-08-2012

The TRILOGY ACS study, the first trial to study patients with acute coronary syndrome who do not undergo…

Bristol-Myers SquibbCardio-vascularDaiichi SankyoEffientEli LillyPharmaceuticalPlavixResearchSanofi

Lilly and Kowa's Livalo meets primary endpoint of LDL-C reduction

01-06-2012

Presenting at the National Lipid Association's (NLA) Scientific Sessions in Scottsdale, Arizona, USA,…

Cardio-vascularEli LillyKowa PharmaceuticalsLivaloPharmaceuticalResearch

EMA unit backs approval of Jentadueto; Agency updates on Pradaxa

28-05-2012

Independent German drug major Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) have received…

Boehringer IngelheimCardio-vascularDiabetesEli LillyEuropeJentaduetoPharmaceuticalPradaxaRegulation

New Zealand approves Effient listing for clopidogrel-allergic patients

19-03-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, has announced reaching agreement with US…

Asia-PacificCardio-vascularEffientEli LillyPharmaceuticalPricingRegulation

Brazilian acute coronary syndrome drug market set to nearly double to $229 million in 2015

01-12-2011

The acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010…

AstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalSouth America

China’s acute coronary syndrome drug market forecast to grow to nearly $450 million in 2015

22-11-2011

The acute coronary syndrome (ACS) drug market in China will grow from $326 million in 2010 to $448 million…

Asia-PacificAstraZenecaBrilintaCardio-vascularEffientEli LillyMarkets & MarketingPharmaceuticalPlavixSanofi

Amylin and Lilly’s diabetes drug Byetta has rapid, powerful anti-inflammatory effect

04-11-2011

Byetta (exenatide), a drug which has been co-developed and now marketed by US biotech firm Amylin (Nasdaq:…

AmylinByettaCardio-vascularDiabetesEli LillyPharmaceuticalResearch

Back to top